Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tamaril is a phytotherapeutic combination product developed by Marjan Industria e Comercio ltda for the treatment of functional intestinal constipation. The formulation consists of several herbal extracts, including *Senna alexandrina* (Senna), *Cassia fistula* (Golden Shower), *Tamarindus indica* (Tamarind), *Coriandrum sativum* (Coriander), and *Periandra mediterranea* (Brazilian Licorice). The primary active constituents are sennosides derived from Senna and Cassia, which function as stimulant laxatives. Upon ingestion, sennosides are converted by colonic bacteria into active metabolites like rheinanthrone, which stimulate the myenteric plexus, increase intestinal peristalsis, and alter electrolyte transport to increase water secretion into the bowel. Tamaril has been evaluated in Phase III clinical trials (e.g., NCT00990951) and is approved for use in patients with functional constipation in Brazil.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tamaril (f24065).